<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866748</url>
  </required_header>
  <id_info>
    <org_study_id>NN9928-4048</org_study_id>
    <secondary_id>2012-003199-38</secondary_id>
    <secondary_id>U1111-1132-4190</secondary_id>
    <nct_id>NCT01866748</nct_id>
  </id_info>
  <brief_title>Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects</brief_title>
  <official_title>Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to investigate the safety,
      tolerability and pharmacokinetics (the effect of the investigated drug on the body) of single
      and multiple doses of a long-acting GLP-1 analogue (semaglutide) in an oral formulation in
      healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Day -1 to Day 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Recorded from the time of first dosing (Visit 3, Day -1 to day +2) and until completion of the post treatment follow-up visit (Visit 18, Day 90-104)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: AUC0-24h,semaglutide: the area under the semaglutide plasma concentration curve</measure>
    <time_frame>From time 0 to 24 hours after a single dose (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: AUCÏ„,semaglutide: area under the semaglutide plasma concentration curve</measure>
    <time_frame>Over the dosing interval (0-24 hours) after the last 3 daily doses (Days 67-69)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in fasting plasma glucose (FPG) from baseline</measure>
    <time_frame>Day 0 (pre-dose), day 70</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in body weight from baseline</measure>
    <time_frame>Day -1, day 70</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (multiple dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.</description>
    <arm_group_label>Part A (single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.</description>
    <arm_group_label>Part B (multiple dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.</description>
    <arm_group_label>Part A (single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).</description>
    <arm_group_label>Part B (multiple dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subject, who is considered to be generally healthy, based on the medical history,
             physical examination, and the results of vital signs, electrocardiogram (ECG) and
             laboratory safety tests performed during the screening visit, as judged by the
             investigator

          -  Body Mass Index (BMI) between 20 and 30 kg/m^2

          -  Glycosylated haemoglobin (HbA1c) below 6.0% (only in Part B)

        Exclusion Criteria:

          -  History of, or presence of, cancer, diabetes or any clinically significant
             cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal (GI),
             endocrinological, haematological, dermatological, venereal, neurological, psychiatric
             diseases or other major disorders, as judged by the investigator

          -  Use of prescription or non-prescription medicinal and herbal products (except routine
             vitamins) within three weeks preceding the dosing. Occasional use of paracetamol or
             acetylsalicylic acid is permitted
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <last_update_submitted>April 25, 2014</last_update_submitted>
  <last_update_submitted_qc>April 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

